Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Moodys
Boehringer Ingelheim
Dow

Last Updated: August 13, 2022

Investigational Drug Information for Seltorexant


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Seltorexant?

Seltorexant is an investigational drug.

There have been 18 clinical trials for Seltorexant. The most recent clinical trial was a Phase 2 trial, which was initiated on September 15th 2020.

The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].

There are four US patents protecting this investigational drug and eighty-nine international patents.

Recent Clinical Trials for Seltorexant
TitleSponsorPhase
A Study of Seltorexant in Participants With Probable Alzheimer's DiseaseJanssen Research & Development, LLCPhase 2
A Study of JNJ-42847922 (Seltorexant) in Healthy ParticipantsJanssen Research & Development, LLCPhase 1
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and ZolpidemJanssen Research & Development, LLCPhase 1

See all Seltorexant clinical trials

Clinical Trial Summary for Seltorexant

Top disease conditions for Seltorexant
Top clinical trial sponsors for Seltorexant

See all Seltorexant clinical trials

US Patents for Seltorexant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Seltorexant See Plans and Pricing Methods of treating depression using orexin-2 receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
Seltorexant See Plans and Pricing Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Janssen Pharmaceutica (BE) See Plans and Pricing
Seltorexant See Plans and Pricing Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators Janssen Pharmaceutica NV (BE) See Plans and Pricing
Seltorexant See Plans and Pricing Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators Janssen Pharmaceutica NV (Beerse, BE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Seltorexant

Drugname Country Document Number Estimated Expiration Related US Patent
Seltorexant Australia AU2017231828 2036-03-10 See Plans and Pricing
Seltorexant Brazil BR112018067906 2036-03-10 See Plans and Pricing
Seltorexant Canada CA2960253 2036-03-10 See Plans and Pricing
Seltorexant Canada CA3016706 2036-03-10 See Plans and Pricing
Seltorexant Chile CL2018002533 2036-03-10 See Plans and Pricing
Seltorexant China CN108883110 2036-03-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Moodys
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.